Cargando…
Pemetrexed single agent chemotherapy in previously treated patients with locally advanced or metastatic non-small cell lung cancer
BACKGROUND: The main objective of this study was to evaluate the safety of second-line pemetrexed in Stage IIIB or IV NSCLC. METHODS: Overall, 95 patients received pemetrexed 500 mg/m(2 )i.v. over Day 1 of a 21-day cycle. Patients also received oral dexamethasone, oral folic acid and i.m. vitamin B1...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2529337/ https://www.ncbi.nlm.nih.gov/pubmed/18667090 http://dx.doi.org/10.1186/1471-2407-8-216 |